Barry D. Quart, Director at SYNAGEVA BIOPHARMA CORP (GEVA), sold 1,000 shares at $83.31 ($83K) on 2014-06-12, disclosed to the SEC on 2014-06-16.
Scheduled sale ($83k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| Filing → |
| KNSA | SELL | 2026-02-12 | $126K | — | Filing → |
| KNSA | SELL | 2026-02-04 | $722K | — | Filing → |
| KNSA | SELL | 2025-12-17 | $1.7M | — | Filing → |